SuperGen Announces Achievement of $20 Million Dacogen™ (decitabine) Injection Milestone

SuperGen Announces Achievement of $20 Million Dacogen(TM) (decitabine) Injection Milestone DUBLIN, Calif., May 26 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG) announced today that the first commercial shipment of Dacogen ™ (decitabine) injection was released by MGI PHARMA, INC. to wholesale drug distributors earlier this week. Under the terms of its exclusive worldwide licensing agreement with MGI PHARMA, SuperGen has achieved the $20 million commercialization milestone. Additionally, SuperGen will earn a royalty on worldwide net sales starting at 20% and escalating to a maximum of 30%. About SuperGen Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen's portfolio includes Orathecin ™ (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent ® (pentostatin for injection), Mitomycin, and Surface Safe ® cleaner. In addition, a number of aurora -A, tyrosine kinase and DNA methyltransferase inhibitors are under development. For more information about SuperGen, please visit http://www.supergen.com. Contacts: SuperGen Noonan Russo Timothy L. Enns Sharon Weinstein S.V.P., Corporate Communications Director of Investor Relations & Business Development Tel: (925) 560-0100 x111 Tel: (212) 845-4271 E-mail: [email protected] E-mail: [email protected] SOURCE SuperGen, Inc. 05/26/2006 CONTACT: Timothy L. Enns, S.V.P., Corporate Communications & Business Development of SuperGen, +1 -925-560-0100 ext. 111, [email protected]; or Sharon Weinstein, Director of Investor Relations of Noonan Russo, +1-212-845-4271, [email protected] Web site: http://www.supergen.com (SUPG)

The release as fetched from its publisher. astx.com ↗